natgillin/translations-raw huggingface dataset:
Patients should not take pantoprazole as a preventive medicinal product. 
Bolesnici ne smiju uzimati pantoprazol profilaktički.
The mechanism leading to the formation of gastric carcinoids by substituted benzimidazoles has been carefully investigated and allows the conclusion that it is a secondary reaction to the massively elevated serum gastrin levels occurring in the rat during chronic high-dose treatment. 
Mehanizam kojim supstituirani benzimidazoli dovode do formiranja gastričkih karcinoida je pomno proučen i zaključeno je da se radi o sekundarnoj reakciji na veliko povećanje serumske razina gastrina koje se javlja u štakora tijekom kroničnog liječenja visokim dozama.
Treatment with acid-reducing medicinal products leads to a slightly increased risk of gastrointestinal infections such as Salmonella, Campylobacter, or Clostridium difficile. 
Liječenje lijekovima koji smanjuju kiselost vodi do blagog povećanja rizika od gastrointestinalnih infekcija s npr. Salmonella, Campylobacter, ili Clostridium difficile.
See ‘Other medicines and PANTOLOC Control'. 
Pogledajte 'Ostali lijekovi i PANTOLOC Control'.
What you need to know before you take PANTOLOC Control 
Što morate znati prije nego počnete uzimati PANTOLOC Control
In the 2-year rodent studies an increased number of liver tumors was observed in rats (in one rat study only) and in female mice and was interpreted as being due to pantoprazole's high metabolic rate in the liver. 
Tijekom 2-godišnjih ispitivanja na glodavcima opažen je povećan broj tumora jetre kod štakora (u samo jednom ispitivanju na štakorima) i ženki miševa, što je protumačeno kao posljedica visoke stope metabolizma pantoprazola u jetri.
What PANTOLOC Control contains - The active substance is pantoprazole. 
Što PANTOLOC Control sadrži - Djelatna tvar je pantoprazol.
By the end of the recovery phase, bone parameters were similar across groups and body weights were also trending toward reversibility after a drug-free recovery period. 
Do kraja faze oporavka, koštani parametri bili su slični u svim ispitivanim skupinama, a tjelesna je težina tijekom razdoblja oporavka bez primjene lijeka pokazivala trend ka reverzibilnosti.
- falling magnesium levels in your blood (potential symptoms: fatigue, involuntary muscle contractions, disorientation, convulsions, dizziness, increased heart rate). 
- smanjenje razine magnezija u krvi(potencijalni simptomi: umor, nevoljno stezanje mišića, dezorijentacija, konvulzije, omaglica, povećan broj otkucaja srca).
In a retrospective analysis of 17 studies in 5960 patients with gastro-oesophageal reflux disease (GORD) who were treated with 20 mg pantoprazole monotherapy, the symptoms associated with acid reflux e.g. heartburn and acid regurgitation were evaluated according to a standardised methodology. 
Retrospektivnom analizom 17 ispitivanja na 5960 bolesnika s gastroezofagealnom refluksnom bolesti (GERB) koji su liječeni monoterapijom s 20 mg pantoprazola, prema standardiziranoj metodologiji su procijenjivani simptomi povezani s refluksom kiseline, npr. žgaravica i regurgitacija kiseline.
The inhibition is dose-dependent and affects both basal and stimulated acid secretion. 
Inhibicija je ovisna o dozi i utječe na bazalnu i stimuliranu sekreciju kiseline.
The occurrence of these neoplasms is associated with the pantoprazole-induced changes in the breakdown of thyroxine in the rat liver. 
Pojava takvih neoplazmi povezana je s pantoprazolom izazvanih promjena u razgradnji tiroksina u jetri štakora.
Pantoprazole is converted to its active form, a cyclic sulphenamide, in the acidic environment in the parietal cells where it inhibits the H+, K+-ATPase enzyme, i. e. the final stage in the production of hydrochloric acid in the stomach. 
Pantoprazol prelazi u svoj aktivni oblik, ciklički sulfenamid, u kiselim uvjetima u parijetalnim stanicama gdje inhibira enzim H+, K+-ATP-azu, tj. završnu fazu proizvodnje kloridne kiseline u želucu.
In a peri-postnatal rat reproduction study designed to assess bone development, signs of offspring toxicity (mortality, lower mean body weight, lower mean body weight gain and reduced bone growth) were observed at exposures (Cmax) approximately 2x the human clinical exposure. 
U peri- postnatalnom reproduktivnom ispitivanju u štakora, dizajniranom za ocjenu razvoja kostiju, znakovi toksičnosti u potomstva (smrtnost, snižena srednja vrijednost tjelesne težine, snižena srednja vrijednost prirasta tjelesne težine i smanjen rast kostiju) zabilježeni su pri izloženostima (Cmax) približno 2x većima od kliničke izloženosti u ljudi.
Concomitant use of high dose methotrexate (e.g. 300 mg) and proton-pump inhibitors has been reported to increase methotrexate levels in some patients. 
Kod istodobne primjene visokih doza metotreksata (npr. 300 mg) i inhibitora protonske pumpe prijavljen je porast razine metotreksata kod nekih bolesnika.
mm/yyyy 
{MM/GGGG}
Do not take PANTOLOC Control with other medicines which limit the amount of acid produced in your stomach, such as another proton pump inhibitor (omeprazole, lansoprazole or rabeprazole) or an H2 antagonist (e.g. ranitidine, famotidine). 
Ne uzimajte PANTOLOC Control s drugim lijekovima koji ograničavaju količinu proizvodnje želučane kiseline, kao što su drugi inhibitor protonske pumpe (omeprazol, lanzoprazol ili rabeprazol) ili H2 antagonist (npr. ranitidin, famotidin).
As the therapeutic dose in man is low, no side effects on the thyroid glands are expected. 
S obzirom da je terapijska doza kod ljudi niska, ne očekuju se nuspojave lijeka na štitnjaču.
Other side effects include: - Common (may affect up to 1 in 10 people): Benign polyps in the stomach 
Ostale nuspojave uključuju: - Česte nuspojave (mogu se javiti u do 1 na 10 osoba): dobroćudni polipi u želucu.
If lesions occur, especially in sun-exposed areas of the skin, and if accompanied by arthralgia, the patient should seek medical help promptly and the health care professional should consider stopping PANTOLOC Control. 
Ako nastupe lezije, posebice na suncem izloženim područjima kože, te ako su popraćene artralgijom, bolesnik treba odmah potražiti medicinsku pomoć, a zdravstveni radnik treba razmotriti prekid liječenja lijekom PANTOLOC Control.
Since pantoprazole binds to the enzyme distal to the receptor level, it can inhibit hydrochloric acid secretion independently of stimulation by other substances (acetylcholine, histamine, gastrin). 
Budući da se pantoprazol veže na enzime distalne razini staničnih receptora, može inhibirati lučenje kloridne kiseline neovisno o stimulaciji drugim tvarima (acetilkolinom, histaminom, gastrinom).
Production site Oranienburg Lehnitzstraße 70-98, 16515 Oranienburg 
Lehnitzstrasse 70-98, 16515 Oranienburg
Packs containing 7 or 14 gastro-resistant tablets. 
Pakiranje sadrži 7 ili 14 želučanootpornih tableta.
It may be necessary to take the tablets for 2-3 consecutive days to relieve the symptoms. 
Možda će biti potrebno uzimati tablete 2-3 uzastopna dana da bi se postiglo olakšanje simptoma.
Yellow, oval biconvex film-coated tablets imprinted with “P20” in brown ink on one side. 
Žute, ovalne, bikonveksne, filmom obložene tablete sa smeđom oznakom "P20" na jednoj strani.
As pantoprazole is extensively protein bound, it is not readily dialysable. 
Kako se pantoprazol u velikoj mjeri veže na proteine, ne dijalizira se lako.
There was no evidence of impaired fertility following the administration of pantoprazole in animal studies (see section 5.3). 
Nije bilo dokaza smanjenja plodnosti nakon primjene pantoprazola u ispitivanjima na životinjama (vidjeti dio 5.3).
Renal elimination represents the major route of excretion (about 80%) for the metabolites of pantoprazole; the rest is excreted with the faeces. 
Metaboliti pantoprazola najvećim se dijelom eliminiraju izlučivanjem putem bubrega (oko 80%), a ostatak se izlučuje stolicom.
• They have jaundice, hepatic impairment, or liver disease. 
• ima žuticu, oštećenje jetre ili bolest jetre.
• They have unintentional weight loss, anaemia, gastrointestinal bleeding, dysphagia, persistent vomiting or vomiting with blood, since it may alleviate symptoms and delay diagnosis of a severe condition. 
• nenamjerno gubi na težini, ima anemiju, gastrointestinalno krvarenje, disfagiju, stalno povraća ili povraća krv, jer u tom slučaju može ublažiti simptome i odgoditi dijagnozu teške bolesti.
• They have had previous gastric ulcer or gastrointestinal surgery. 
• ima gastrički ulkus ili operaciju gastrointestinalnog trakta u anamnezi.
Therefore in settings where high-dose methotrexate is used, for example cancer and psoriasis, a temporary withdrawal of pantoprazole may need to be considered. 
Stoga u okolnostima kad se primjenjuju visoke doze metotreksata, na primjer kod karcinoma ili psorijaze, treba razmisliti o privremenom prestanku primjene pantoprazola.
If you forget to take PANTOLOC Control 
Ako ste zaboravili uzeti PANTOLOC Control
However, you may take PANTOLOC Control with antacids (e.g. magaldrate, alginic acid, sodium bicarbonate, aluminium hydroxide, magnesium carbonate, or combinations thereof), if needed. 
Ako je potrebno, PANTOLOC Control možete uzimati s antacidima (npr. megaldrat, alginatna kiselina, natrijev bikarbonat, aluminijev hidroksid, magnezijev karbonat ili kombinacije navedenih).
Pantoprazole reduces acidity in the stomach and thereby increases gastrin in proportion to the reduction in acidity. 
Pantoprazol smanjuje kiselost u želucu, a proporcionalno smanjenju kiselosti povećava se razina gastrina.
After 7 days the percentage of patients experiencing complete relief from acid regurgitation was between 61.5% and 84.4%, after 14 days between 67.7% and 90.4%, and after 28 days between 75.2% and 94.5%, respectively. 
Kod 61,5% do 84,4% bolesnika regurgitacija kiseline je potpuno nestala nakon 7 dana, kod 67,7% do 90,4% nakon 14 dana, a kod 75,2% do 94,5% nakon 28 dana.
- The other ingredients are: - Core: sodium carbonate (anhydrous), mannitol, crospovidone, povidone K90, calcium stearate. 
- Drugi sastojci su: - Jezgra: natrijev karbonat (bezvodni), manitol, krospovidon, povidon K90, kalcijev stearat.
Serious manifestations of hypomagnesaemia such as fatigue, tetany, delirium, convulsions, dizziness, and ventricular arrhythmia can occur but they may begin insidiously and be overlooked. 
Mogu se pojaviti ozbiljne manifestacije hipomagnezijemije kao što su umor, tetanija, delirij, konvulzije, omaglica i ventrikularna aritmija, čiji nastup može biti podmukao i može ga se previdjeti.
This should be considered in patients with reduced body stores or risk factors for reduced vitamin B12 absorption on long-term therapy or if respective clinical symptoms are observed. 
To se mora uzeti u obzir kod bolesnika sa smanjenim zalihama ili čimbenicima rizika za smanjenju apsorpciju vitamina B12 na dugotrajnoj terapiji ili ako se pojave klinički simptomi nedostatka vitamina B12.
PANTOLOC Control should not be used during breast-feeding. 
Pantoloc Control ne smije se koristiti tijekom dojenja.
The following adverse reactions have been reported with pantoprazole. 
Prijavljene su sljedeće nuspojave pantoprazola.
As a result, concentration of pantoprazole in the foetus is increased shortly before birth. 
Zbog toga je neposredno prije rođenja kod fetusa povećana koncentracija pantoprazola.
Although no interaction during concomitant administration of phenprocoumon or warfarin has been observed in clinical pharmacokinetic studies, a few isolated cases of changes in International Normalised Ratio (INR) have been reported during concomitant treatment in the post-marketing period. 
Iako u kliničkim farmakokinetičkim ispitivanjima nisu opažene interakcije kod istodobne primjene fenprokumona ili varfarina s pantoprazolom, nakon stavljanja lijeka u promet prijavljeno je nekoliko izoliranih slučajeva promjene INR-a (međunarodnog normaliziranog omjera) tijekom istodobne primjene tih lijekova.
Marketing Authorisation Holder Takeda GmbH 
Nositelj odobrenja za stavljanje lijeka u promet Takeda GmbH
What PANTOLOC Control looks like and contents of the pack The gastro-resistant tablets are yellow, oval, biconvex film-coated tablets imprinted with “P20” on one side. 
Kako PANTOLOC Control izgleda i sadržaj pakiranja Želučanootporne tablete su žute, ovalne, bikonveksne, filmom obložene tablete sa smeđom oznakom "P20" na jednoj strani.
It might be necessary to take the tablets for 2-3 consecutive days to achieve improvement of symptoms. 
Tablete je ponekad potrebno uzimati 2-3 uzastopna dana da bi se postiglo poboljšanje simptoma.
Disorientation (and all aggravations) 
dezorijentirano st (i pogoršanje istog)
For patients expected to be on prolonged treatment or who take PPIs with digoxin or medicinal products that may cause hypomagnesaemia (e.g. diuretics), health care professionals should consider measuring magnesium levels before starting PPI treatment and periodically during treatment. 
Za bolesnike kod kojih se očekuje da će biti na dugotrajnoj terapiji inhibitorima protonske pumpe ili za bolesnike koji istodobno uzimaju digoksin ili druge lijekove koji mogu uzrokovati hipomagnezijemiju (npr. diuretici), liječnici moraju razmotriti praćenje razine magnezija prije uvođenja inhibitora protonske pumpe u terapiju i periodično tijekom liječenja.
Increased Chromogranin A (CgA) level may interfere with investigations for neuroendocrine tumours. 
Povišena razina kromogranina A (CgA) može interferirati s pretragama za neuroendokrine tumore.
PANTOLOC Control may reduce the absorption of active substances whose bioavailability is dependent on the gastric pH (e.g. ketoconazole). 
PANTOLOC Control može smanjiti apsorpciju djelatnih tvari čija bioraspoloživost ovisi o pH želuca (npr. ketokonazol).
Pharmacotherapeutic group: Drugs for acid related disorders, Proton pump inhibitors, ATC code: A02BC02 
Inhibitori protonske pumpe, ATK oznaka: A02BC02
Pantoprazole, as all acid-blocking medicines, may reduce the absorption of vitamin B12 (cyanocobalamin) due to hypo- or achlorhydria. 
Kao i svi lijekovi koji blokiraju kiselinu, pantoprazol može smanjiti apsorpciju vitamina B12 (cijanokobalmin) zbog hipoklorhidrije ili aklorhidrije.
Other medicines and PANTOLOC Control 
Drugi lijekovi i PANTOLOC Control
Acid-reflux symptom relief rates were largely independent of the initial GORD stage. 
Stope olakšanja simptoma refluksa kiseline su u velikoj mjeri ovisile o početnom stupnju GERB-a.
Do not use this medicine after the expiry date, which is stated on the carton and the blister after ‘EXP'. 
Ovaj lijek se ne smije upotrijebiti nakon isteka roka valjanosti navedenog na kutiji i na blisteru iza „Rok valjanosti“.
During treatment with antisecretory medicinal products, serum gastrin increases in response to the decreased acid secretion. 
Vrijednosti serumskog gastrina rastu tijekom liječenja antisekretornim lijekovima kao odgovor na smanjeno lučenje kiseline.
On average, at about 2.0 h - 2.5 h post administration (tmax) of a single 20 mg oral dose, the maximum serum concentrations (Cmax) of about 1-1.5 µg/ml are achieved, and these values remain constant after multiple administration. 
Nakon jednokratne peroralne doze od 20 mg, prosječno se maksimalna koncentracija u serumu (Cmax) od oko 1-1,5 μg/ml postiže oko 2 do 2,5 sata nakon primjene (tmax) i ta vrijednost se ne mijenja nakon višekratne primjene.
The increased CgA level may interfere with investigations for neuroendocrine tumours. 
Povišena razina CgA može interferirati s pretragama za neuroendokrine tumore.
Patients with long-term recurrent symptoms of indigestion or heartburn should see their doctor at regular intervals. 
Bolesnici s dugotrajnim ili opetovanim simptomima indigestije ili žgaravice moraju redovito posjećivati liječnika.
In most affected patients, hypomagnesaemia improved after magnesium replacement and discontinuation of the PPI. 
U većine pogođenih bolesnika, hipomagnezijemija se poboljšala nakon nadoknade magnezija i prekida terapije inhibitorom protonske pumpe.
As a result, a mild to moderate increase in the number of specific endocrine (ECL) cells in the stomach is observed in a minority of cases during long-term treatment (simple to adenomatoid hyperplasia). 
Kao rezultat toga je u malom broju slučajeva uočeno blago do umjereno povećanje broja specifičnih endokrinih stanica u želucu (jednostavna do adenomatoidna hiperplazija) tijekom dugotrajnog liječenja.
Therefore, in patients treated with coumarin anticoagulants (e.g. phenprocoumon or warfarin), monitoring of prothrombin time/INR is recommended after initiation, termination or during irregular use of pantoprazole. 
Zbog toga se kod bolesnika koji se liječe kumarinskim antikoagulansima (npr. fenprokumon ili varfarin) preporučuje nakon početka, završetka ili tijekom neredovite primjene pantoprazola pratiti protrombinsko vrijeme/INR.
Liver enzymes increased (transamina ses, γ-GT) 
Poremećaji jetre i žuči povišenje jetrenih enzima (transaminaze, γ-GT)
Preclinical studies revealed no evidence of impaired fertility or teratogenic effects (see section 5.3). 
Pretklinička ispitivanja nisu dokazala oštećenu plodnost ili teratogene učinke (vidjeti dio 5.3).
Patients may start to experience symptomatic relief after approximately one day of treatment with pantoprazole, but it might be necessary to take it for 7 days to achieve complete heartburn control. 
Poboljšanje simptoma može nastupiti već nakon prvog dana liječenja s pantoprazolom, no ponekad je potrebno uzimati ga 7 dana da bi se postigla potpuna kontrola žgaravice.
Tell your doctor immediately, before or after taking this medicine, if you notice any of the following symptoms, which could be a sign of another, more serious, disease: - an unintentional loss of weight (not related to a diet or an exercise programme) - vomiting, particularly if repeated - vomiting blood; this may appear as dark coffee grounds in your vomit - you notice blood in your stools; which may be black or tarry in appearance - difficulty in swallowing or pain when swallowing - you look pale and feel weak (anaemia) - chest pain - stomach pain - severe and/or persistent diarrhoea, because this medicine has been associated with a small increase in infectious diarrhoea. 
Odmah obavijestite svog liječnika, prije ili nakon uzimanja ovog lijeka, ako primijetite neki od sljedećih simptoma koji može biti znak druge, ozbiljnije bolesti: - nenamjeran gubitak težine (koji nije vezan uz dijetu ili program tjelovježbe) - povraćanje, osobito ako se ponavlja - povraćanje krvi, što možete primijetiti u obliku tamnih zrnaca veličine zrna kave - krv u stolici, koja može biti crna ili poput katrana - teškoće pri gutanju ili bol pri gutanju - bljedoća ili osjećaj slabosti (anemija) - bol u prsnom košu - bol u trbuhu - težak i/ili stalan proljev, jer je ovaj lijekpovezan sa malim porastom zaraznog proljeva.
Posology The recommended dose is 20 mg pantoprazole (one tablet) per day. 
Doziranje Preporučena doza je 20 mg pantoprazola (jedna tableta) na dan.
If no symptom relief is obtained within 2 weeks of continuous treatment, the patient should be instructed to consult a doctor. 
Ukoliko se nakon 2 tjedna kontinuiranog liječenja simptomi ne povuku, bolesnika se mora uputiti da potraži savjet liječnika.
Patients should not take another proton pump inhibitor or H2 antagonist concomitantly. 
Bolesnici ne smiju istodobno uzimati dodatni inhibitor protonske pumpe ili antagonist
Special populations No dose adjustment is necessary in elderly patients or in those with impaired renal or liver function. 
Posebne populacije Za starije bolesnike i one s oštećenom funkcijom jetre ili bubrega nije potrebna prilagodba doze.
If you have been suffering from repetitive heartburn or indigestion symptoms for some time, remember to see your doctor regularly. 
Ako duže vrijeme patite od žgaravice ili probavnih smetnji, redovito posjećujte liječnika.
Driving and using machines If you experience side effects like dizziness or disturbed vision, you should not drive or use machines. 
Ako se kod Vas pojave nuspojave poput omaglice ili poremećaja vida, ne smijete upravljati vozilima niti raditi na strojevima.
Pantoprazole is completely and rapidly absorbed after oral administration. 
Pantoprazol se nakon peroralne primjene potpuno i brzo apsorbira.
Subacute cutaneous lupus erythematosus (see section 
Subakutni kožni lupus eritematodes (pogledajte dio
During long-term treatment, gastrin levels double in most cases. 
Tijekom dugotrajnog liječenja vrijednosti gastrina se u većini slučajeva udvostručuju, ali njihovo pretjerano povećanje se javlja samo u pojedinačnim slučajevima.
- Very rare side effects (may affect up to 1 in 10,000 people): disorientation; reduction in the number of blood platelets, which may cause you to bleed or bruise more than normal; reduction in the number of white blood cells, which may lead to more frequent infections; coexisting abnormal reduction in the number of red and white blood cells, as well as platelets (seen in blood tests). 
- Vrlo rijetke nuspojave(mogu se javiti udo 1 na 10000 osoba): dezorijentiranost; smanjenje broja krvnih pločica što može uzrokovati neuobičajena krvarenja i stvaranja modrica; smanjenje broja bijelih krvnih stanica što može dovesti do učestalih infekcija; istovremeno abnormalno smanjenje broja crvenih i bijelih krvnih stanica, te krvnih pločica (vidljivo na krvnim pretragama).
- You should not take PANTOLOC Control tablets for more than 4 weeks without consulting a doctor. 
- Ne smijete uzimati PANTOLOC Control tablete dulje od 4 tjedna bez savjetovanja s liječnikom.
This medicine may not bring immediate relief. 
Ovaj lijek ne mora trenutno ublažiti simptome.
You may experience relief from your acid reflux and heartburn symptoms after just one day of treatment with PANTOLOC Control, but this medicine is not meant to bring immediate relief. 
Možete osjetiti olakšanje od simptoma refluksa kiseline ili žgaravice nakon samo jednog dana liječenja s PANTOLOC Control, ali ovaj lijek nije namijenjen trenutnom olakšanju simptoma.
Decreased gastric acidity, due to any means - including proton pump inhibitors - increases gastric counts of bacteria normally present in the gastrointestinal tract. 
Gastrointestinalne infekcije izazvane bakterijama Smanjena kiselost u želucu koja nastaje iz bilo kojeg razloga - uključujući uzimanje inhibitora protonske pumpe - povećava brojnost bakterija koje su inače prisutne u gastrointestinalnom traktu.
Pantoprazole is a substituted benzimidazole which inhibits the secretion of hydrochloric acid in the stomach by specific blockade of the proton pumps of the parietal cells. 
Pantoprazol je supstituirani benzimidazol koji specifičnom blokadom protonskih pumpi parijetalnih stanica želuca inhibira izlučivanje kloridne kiseline.
- Coating: hypromellose, povidone, titanium dioxide (E171), yellow iron oxide (E172), propylene glycol, methacrylic acid-ethyl acrylate copolymer, sodium lauril sulfate, polysorbate 80, triethyl citrate. 
- Ovojnica: hipromeloza, povidon, titanijev dioksid (E171), žuti željezov oksid (E172), propilenglikol, metakrilatna kiselina/etilakrilat kopolimer 1:1, natrijev laurilsulfat, polisorbat 80, trietilcitrat.
Microscopic colitis 
Mikroskopski kolitis
Hypocalcemia in association with hypomagnesemia 
Hipokalcijemija povezana s hipomagnezijemijom
Proton pump inhibitors are associated with very infrequent cases of SCLE. 
Subakutni kožni lupus eritematodes (SCLE, engl. subacute cutaneous lupus erythematosus) Inhibitori protonske pumpe povezani su s vrlo rijetkim slučajevima SCLE-a.
D-78467 Konstanz Germany 
2 78467 Konstanz Njemačka
Do not take PANTOLOC Control tablets for more than 4 weeks without consulting your doctor. 
Nemojte uzimati PANTOLOC Control tablete dulje od 4 tjedna bez savjetovanja s liječnikom.
Hypocalcaemia 
Hipomagnezijemija
Not known 
Vrlo rijetke Nepoznato
Clearance is about 0.1 l/h/kg, and terminal half-life (t1/2) about 1 h. There were a few cases of subjects with delayed elimination. 
Klirens je oko 0,1 l/h/kg, a poluvijek (t1/2) oko 1 sat.